Mesoblast (MESO) Cash & Equivalents (2015 - 2025)

Mesoblast (MESO) has reported Cash & Equivalents for 11 consecutive years, with $130.0 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents rose 241.78% year-over-year to $130.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $130.0 million (up 241.78% YoY) and the FY2025 annual result came in at $161.6 million, up 156.59% from the prior year.
• Cash & Equivalents retreated to $130.0 million in Q4 2025 per MESO's latest filing, from $161.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MESO reached as high as $161.2 million in Q2 2025 and fell as low as $38.0 million in Q4 2024.
• A 5-year average of $92.4 million and a median of $77.6 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 55.84% — and 2025, when it surged 241.78%.
• Year by year, Cash & Equivalents stood at $94.8 million in 2021, then dropped by 28.71% to $67.6 million in 2022, then rose by 14.69% to $77.6 million in 2023, then plunged by 50.96% to $38.0 million in 2024, then jumped by 241.78% to $130.0 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $130.0 million, $161.2 million, and $38.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.